Scholars Central

Conference abstractPublished 29 Nov 2017

In the search of safe therapies for Down syndrome

Authors: Fiorenza Stagni

University of Bologna, Italy

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

No therapies currently exist for intellectual disability in Down syndrome (DS), a relatively high-incidence genetic condition (1:700/1000). Neurogenesis impairment starting from fetal life stages is considered a major determinant of intellectual disability in DS. We have previously shown that perinatal treatment with fluoxetine, an antidepressant, fully restores neurogenesis and cognitive performance in the Ts65Dn mouse model of DS. The finding that these effects were accompanied by an increase in the levels of brain-derived neurotrophic factor (BDNF) suggests that BDNF may be an important determinant of the proneurogenic effect of fluoxetine. This important discovery prompted us to find a therapy that is as effective as fluoxetine but that may pose fewer caveats for clinical application in children with DS. A therapy based on BDNF is impracticable due to its poor blood-brain barrier penetration. However, the naturally-occurring flavone 7,8-DHF is a BDNF mimetic that crosses the blood-brain barrier and binds to the BDNF TrkB receptor. Based on these premises, the goal of our study was to establish whether early treatment with 7,8-DHF can rescue trisomy-linked neurodevelopmental defects, similarly to fluoxetine. We found that neonatal treatment with 7,8-DHF increased neurogenesis and restored neuron maturation in the hippocampus of Ts65Dn mice. Importantly, Ts65Dn mice treated from birth to adolescence exhibited restoration of hippocampus-dependent memory. This study provides novel evidence that treatment with a natural compound 7,8-DHF restores brain development and cognitive performance in a DS mouse model. In view of the safe nature of 7,8-DHF our results, potentially, are readily transferable into clinical practice.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • BylineArticles whose byline prints “Fiorenza Stagni”